Ask about this productRelated genes to: GART antibody
- Gene:
- GART NIH gene
- Name:
- phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase
- Previous symbol:
- PRGS, PGFT
- Synonyms:
- GARS-AIRS-GART
- Chromosome:
- 21q22.11
- Locus Type:
- gene with protein product
- Date approved:
- 2001-06-22
- Date modifiied:
- 2017-11-24
Related products to: GART antibody
Related articles to: GART antibody
- This study evaluates the time efficiency and safety of Wide Awake Local Anesthesia No Tourniquet (WALANT) compared to general/plexus anesthesia in emergency hand surgery. This single-center, retrospective study analyzed 812 emergency category 2b hand surgeries performed between 2018 and 2024. Patients were divided into 2 groups: local anesthesia (LA), including WALANT, and general/plexus anesthesia. In collaboration with the Institute for Medical Statistics and Biometry, "time to intervention" and postoperative surgical complications were prospectively defined as co-primary endpoints. In addition, a descriptive analysis of the study population was conducted, and a matched-pair analysis was performed to account for injury complexity. Statistical analysis included -tests, Cohen's d, and Gart and Nam's method for risk difference. The mean "time to intervention" was significantly shorter in the LA group (2.2 hours) compared to that in the general/plexus anesthesia group (4.1 hours). Postoperative surgical complication rates were comparable between the LA (8.5%) and general/plexus anesthesia (8.2%) groups, with no significant difference observed. WALANT showed a lower complication rate (5.7%) than LA without epinephrine (9.8%). A matched-pair analysis confirmed these findings. Among the general/plexus anesthesia cases, 16.2% exceeded the recommended 6-hour treatment window, compared to 6.6% in the LA group. Wide Awake Local Anesthesia No Tourniquet facilitates faster treatment of emergency hand surgery cases while maintaining equivalent quality of care compared to general/plexus anesthesia. This study highlights the time efficiency and safety of WALANT in emergency settings, supporting its broader application. - Source: PubMed
Publication date: 2026/04/30
Hohenstein Ayla AMatros RomanNguyen Cam TuFricke MarkEisenhardt Steffen ULeibig Nico - Asthma is a heterogeneous disease characterized by chronic airway inflammation and airway hyperresponsiveness. It represents the most common chronic respiratory condition in children and remains a highly prevalent disorder worldwide. - Source: PubMed
Publication date: 2026/04/11
Dai YunyunYao HefengYang ZihanWang JunyangYin LeyiMao Wei - Leishmaniasis is a vector-borne disease caused by a protozoan parasite of the genus . The infection is transmitted by the bite of infected female sandflies of the genus in the Old World or in the New World. The diagnosis is made by stained smear microscopy, in vitro culture, and DNA-based detection methods. - Source: PubMed
Publication date: 2026/03/18
Al-Jawabreh HananEreqat SuheirAl-Jawabreh AmerDana LinaNasereddin Abedelmajeed - Precision oncology workflows rely heavily on genomic identification of oncogenic driver mutations or the functional loss of tumor suppressors. These pipelines can identify single-agent treatments for patients, but monotherapy is often insufficient and can drive resistance. Recently, functional drug screening has been employed to evaluate tumor-specific drug sensitivities that complement molecular testing. We describe a resistance evaluation after first line exposure (REFLEX) multi-omic paradigm using drug-induced molecular changes to prioritize effective hits from combination screening. In KRAS-mutant cancer models, trametinib treatment caused dysregulation of the purine biosynthetic pathway driven by reductions in enzyme GART. This induced vulnerability nominated purine analog 6-thioguanine as a synergistic partner. Across diverse KRAS-mutant lineages, trametinib-induced GART loss predicts sensitivity to the combination. , the treatment significantly increases overall survival without systemic toxicity. Integrating drug-induced multi-omic changes with functional screening identifies therapeutic strategies, supporting the use of purine analogs with MEK inhibitors for KRAS-mutant tumors. - Source: PubMed
Publication date: 2026/02/07
De Boni LambertoClaridge SallyNath ShaliniTofani KassianneStein Benjamin DPark EricSteiner SabrinaElemento OlivierPauli ChantalHopkins Benjamin D - A 6 month subchronic toxicity study demonstrated that exposure to the mineral oil saturated hydrocarbon (MOSH) subfraction (predominant carbon range C) induced dose- and gender-dependent immunometabolic disruption in Fischer 344 rats. Both low- (1.5 g/kg) and high-dose (15 g/kg) exposure significantly reduced the arterial blood CD4/CD8 T-cell ratio in both genders (female: 1.85 ± 0.40 and 1.27 ± 0.13 vs 3.14 ± 0.20 in controls; male: 1.04 ± 0.39 and 0.95 ± 0.26 vs 4.38 ± 0.54 in controls), indicating concomitant immune dysregulation and inflammation. Integrated metabolomic and proteomic analyses of the spleen elucidated distinct gender-associated responses. Females exhibited upregulated purine metabolism, evidenced by elevated purine intermediates (5-aminoimidazole ribonucleotide and 5'-phosphoribosyl--formylglycinamide) and increased expression of proteins involved in de novo synthesis (PRPS1, GART, and ADSS2) and salvage pathways (adenylate kinase 3, guanine deaminase, and GMPR). In contrast, males displayed a dual pathophysiological pattern characterized by systemic purine activation alongside suppressed mitochondrial energy metabolism (PDHB, HK1, and ACSS1), impaired glutathione homeostasis (GSR and GSTA4), and downregulated heme metabolism (ALAS2, HMBS, CPOX, FECH, HMOX1, and CP). These alterations were consistently more pronounced in the high-dose group. The findings reveal gender-specific immunometabolic toxicity of the MOSH C subfraction, highlighting the necessity of incorporating gender-specific effects and immunometabolic endpoints in future risk assessment of MOSH exposure. - Source: PubMed
Publication date: 2026/02/27
Zhu LinZhang MingmingZhang HongZhang HaiGao BoyanYu Liangli LucyZhang Yaqiong